Page 34 - 2019_12-Haematologica-web

R.A.L. de Groen et al.
113. Yu S, Luo H, Pan M, et al. High frequency
and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. Oncol Lett. 2018;15(2):1707-1715.
114. Lee YS, Liu J, Fricano KA, et al. Lack of a Prognostic impact of the MyD88 L265P mutation for diffuse large B cell lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(12): 2199-2204.
115. Parry M, Rose-Zerilli MJ, Ljungstrom V, et al. Genetics and prognostication in splenic mar- ginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174-4183.
116. Gertz MA. Waldenstrom macroglobuline- mia: 2019 update on diagnosis, risk stratifi- cation, and management. Am J Hematol. 2019;94(2):266-276.
117. Treon SP, Gustine J, Xu L, et al. MYD88 wild- type Waldenstrom macroglobulinaemia: dif- ferential diagnosis, risk of histological trans- formation, and overall survival. Br J Haematol. 2018;180(3):374-380.
118.Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia. Blood Adv. 2018;2(21): 2937-2946.
119.Weber ANR, Cardona Gloria Y, Cinar O, Reinhardt HC, Pezzutto A, Wolz OO. Oncogenic MYD88 mutations in lym- phoma: novel insights and therapeutic pos- sibilities. Cancer Immunol Immunother. 2018;67(11):1797-1807.
120.Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS pymphoma. Cancer Discov. 2017;7(9):1018-1029.
121.Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxoru- bicin, vincristine, and prednisone in non-ger- minal center B-cell diffuse large B-cell lym- phoma. J Clin Oncol. 2019;37 (15):1285- 1295.
122.Chen JG, Liu X, Munshi M, et al. BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type)
MYD88-mutated cells by a paracrine mech-
anism. Blood. 2018;131(18):2047-2059. 123.Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J
Med. 2014;370(24):2286-2294.
124.Cao Y, Hunter ZR, Liu X, et al. CXCR4
WHIM-like frameshift and nonsense muta- tions promote ibrutinib resistance but do not supplant MYD88(L265P) -directed sur- vival signalling in Waldenstrom macroglob- ulinaemia cells. Br J Haematol. 2015;168(5): 701-707.
125. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.
126. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory man- tle cell lymphoma (ACE-LY-004): a single- arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667.
127. Trotman J, Opat S, Marlton P, et al. Bruton's tyrosine kinase (Btk) inhibitor Bgb-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenström macroglobulinemia (Wm). Hematol Oncol. 2017;35(S2):70-71.
128.Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89 (3):237-242.
129. Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selec- tive PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742-1752.
130. He Y, Li J, Ding N, et al. Combination of enzastaurin and ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. J Exp Clin Cancer Res. 2019;38(1):86.
131.Liu X, Hunter ZR, Xu L, et al. Targeting myddosome assembly in Waldenstrom macroglobulinaemia. Br J Haematol. 2017;177(5):808-813.
132.Nelde A, Walz JS, Kowalewski DJ, et al. HLA class I-restricted MYD88 L265P-
derived peptides as specific targets for lym- phoma immunotherapy. Oncoimmunology. 2017;6(3):e1219825.
133.Nielsen JS, Chang AR, Wick DA, et al. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017;6(7):e1321184.
134.Qiu H, Gong S, Xu L, et al. MYD88 L265P mutation promoted malignant B cell resist- ance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade. Int Immunopharmacol. 2018;64:394-400. Camus V, Jardin F, Tilly H. The value of liq- uid biopsy in diagnosis and monitoring of diffuse large B-cell lymphoma: recent devel- opments and future potential. Expert Rev Mol Diagn. 2017;17(6):557-566.
135.
136.
Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
137. Hattori K, Sakata-Yanagimoto M, Kusakabe M, et al. Genetic evidence implies that pri- mary and relapsed tumors arise from com- mon precursor cells in primary central nerv- ous system lymphoma. Cancer Sci. 2019;110(1):401-407.
138. Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic muta- tions in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(9):2171-2179.
139.Bohers E, Viailly PJ, Becker S, et al. Non- invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-through- put targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8(8):74.
140.Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B- cell lymphoma. J Clin Oncol. 2018;36(28): 2845-2853.
141.Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lym- phoma. Leukemia. 2011;25(2):341-347.
2348
haematologica | 2019; 104(12)